logo-loader
RNS
Feedback PLC

Feedback PLC - Statement re Online Commentary

RNS Number : 2506I
Feedback PLC
07 August 2019
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain

 

Feedback plc

Statement re Online Commentary

Cambridge, 7 August 2019: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, notes the recent online commentary regarding a proposed equity fundraising by the Company. 

The Company confirms that, in order to develop BleepaTM, the Company's clinical messaging product, it is currently working on completing a placing of new shares. There can be no certainty that such fundraising will be concluded nor as to the timing or terms of such, but a further announcement will be made as required as soon as possible.

-Ends-

Enquiries: 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

 

+44 (0)1954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

 

+44 (0)20 3328 5656

Peterhouse Capital Ltd (Joint Broker)

Lucy Williams / Duncan Vasey

 

+44 (0)20 7469 0936

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

 

Instinctif Partners

Rozi Morris/ Deborah Bell/ Phillip Marriage

+44 20 3815 8880

 

 

+44 (0)20 7457 2020

feedbackplc@instinctif.com

 

Notes to editors

About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbk.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRLIFSATVIDIIA
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read